Welcome to our dedicated page for Bluejay Diagnostics SEC filings (Ticker: BJDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bluejay Diagnostics filings document the company’s medical diagnostics business, Nasdaq-listed common stock, and disclosures tied to development of the Symphony™ near-patient testing platform. Form 8-K reports cover corporate updates, financial condition items, Regulation FD disclosures, SYMON clinical-study updates, conference-related product disclosures, manufacturing readiness, and capitalization matters involving warrants and private placements.
The company’s proxy materials describe annual meeting proposals, voting procedures, board and governance matters, and stockholder approval topics. Bluejay’s filings also identify it as an emerging growth company and include formal disclosures on material agreements, registered securities, risk-relevant development activities, and capital-structure changes such as reverse stock splits and warrant exercises.
Bluejay Diagnostics, Inc. reports successful completion of patient enrollment in its SYMON-II multicenter clinical validation study, reaching its target of 750 sepsis patients ahead of plan. SYMON-II is a pivotal study evaluating the Symphony IL-6 test for early assessment of 28-day all-cause mortality risk in ICU sepsis patients.
Preliminary observations show an approximately 17% 28-day mortality rate in the enrolled population, providing a large dataset to assess the prognostic utility of IL-6. The company states that SYMON-II is intended to validate earlier findings and is part of a clinical program it plans to use to support a future FDA 510(k) application and potential commercialization of its investigational Symphony rapid, near-patient diagnostic platform.
Bank of America Corporation, Bank of America N.A. and BofA Securities, Inc. jointly state that their beneficial ownership in Bluejay Diagnostics, Inc. has fallen below 10 percent, so they are no longer treated as Section 16 ten percent owners.
Bluejay Diagnostics, Inc. received an initial insider ownership report from Bank of America Corporation and its subsidiaries Bank of America N.A. and BofA Securities, Inc. The statement lists 8 shares of common stock as indirectly beneficially owned through these subsidiaries, and notes they may be deemed to have temporarily held voting and dispositive power over additional shares as a result of short-term stock borrowings.
HRT Financial LP, a ten percent owner of Bluejay Diagnostics, Inc., reported mixed trading in the company’s common stock. On July 9, 2026, it executed an open-market purchase of 64,047 shares at $1.51 per share. On July 10, 2026, it made an open-market sale of 34,938 shares at $1.40 per share. After these transactions, HRT Financial LP directly held 92,055 shares of Bluejay Diagnostics common stock, reflecting a net increase of 29,109 shares over the two days.
HRT Financial LP filed an initial statement of beneficial ownership as a ten percent owner of Bluejay Diagnostics, Inc.. The filing reports direct ownership of 126,993 shares of Common Stock as of July 9, 2026, with no specific buy or sell transaction disclosed.
Bluejay Diagnostics, Inc. received a Form 4 filing from three related institutional holders: BANK OF AMERICA CORP /DE/, BOFA SECURITIES, INC., and BANK OF AMERICA NA. Each is identified as a ten percent owner of Bluejay Diagnostics, but this filing does not list any specific share transactions or option exercises, functioning instead as a beneficial ownership report.
Bank of America Corporation, together with subsidiaries Bank of America N.A. and BofA Securities, Inc., filed an initial ownership report for Bluejay Diagnostics, Inc. The filing lists indirect beneficial ownership of 8 shares of common stock as of July 7, 2026, held through Bank of America N.A. and BofA Securities, Inc. The reporting persons note they may have temporarily held additional shares via short-term stock borrowings and expressly disclaim being part of any group for Section 13(d) purposes.
Bluejay Diagnostics, Inc. registers 11,223,665 shares of common stock for resale by selling stockholders, comprised of shares issuable upon exercise of Pre-Funded Warrants, Series G Warrants, Series H Warrants and Placement Agent Warrants issued June 5, 2026. The company is not selling shares and will not receive proceeds from resales.
The issuer will receive net proceeds only if the Warrants are exercised for cash; the prospectus notes we will receive the net proceeds of any Warrants exercised for cash. The registration limits certain exercises by holders under 4.99% or 9.99% beneficial ownership caps and states shares outstanding were 1,034,715 as of June 17, 2026.
Bluejay Diagnostics, Inc. files a registration to permit resale of up to 11,223,665 shares of its common stock by identified selling stockholders. The shares consist of common stock issuable upon exercise of pre-funded warrants, Series G and H warrants, and placement agent warrants issued June 5, 2026.
The Company is not selling any shares under this prospectus and will not receive proceeds from resales; Bluejay will receive the net proceeds only if the warrants are exercised for cash. The prospectus covers resale methods, selling limits (including 4.99%/9.99% ownership caps), and plan-of-distribution alternatives.